FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142300947> ?p ?o ?g. }

• W2142300947 endingPage "79" @default.
• W2142300947 startingPage "77" @default.
• W2142300947 abstract "Medically refractory neonatal seizures represent a major therapeutic challenge in neonatal intensive care units. Conventional antiepileptic drugs demonstrate limited efficacy. Previous studies documented a high frequency of off-label drug therapy in neonates. We sought to determine if pediatric neurologists are recommending treatment of neonatal seizures with newer agents, despite a lack of information about their safety or efficacy in this population. Surveys were distributed at the 2007 Annual Meeting of the Child Neurology Society. Responses from 55 pediatric neurologists were analyzed. Seventy-three percent (40/55) recommended treatment of neonatal seizures with one or both of levetiracetam and topiramate; 47% (26/55) recommended levetiracetam; and 55% (30/55) recommended topiramate. Despite an absence of data on neonatal pharmacokinetics of either drug, neurologists made different dosing recommendations for these two drugs (P = 0.003, chi-square test). Respondents considered both agents to be efficacious in the majority of cases; adverse effects were recognized more frequently with topiramate. These results highlight the urgent need for rigorous clinical trials to understand the risks and benefits of new drug therapies for neonatal seizures. Medically refractory neonatal seizures represent a major therapeutic challenge in neonatal intensive care units. Conventional antiepileptic drugs demonstrate limited efficacy. Previous studies documented a high frequency of off-label drug therapy in neonates. We sought to determine if pediatric neurologists are recommending treatment of neonatal seizures with newer agents, despite a lack of information about their safety or efficacy in this population. Surveys were distributed at the 2007 Annual Meeting of the Child Neurology Society. Responses from 55 pediatric neurologists were analyzed. Seventy-three percent (40/55) recommended treatment of neonatal seizures with one or both of levetiracetam and topiramate; 47% (26/55) recommended levetiracetam; and 55% (30/55) recommended topiramate. Despite an absence of data on neonatal pharmacokinetics of either drug, neurologists made different dosing recommendations for these two drugs (P = 0.003, chi-square test). Respondents considered both agents to be efficacious in the majority of cases; adverse effects were recognized more frequently with topiramate. These results highlight the urgent need for rigorous clinical trials to understand the risks and benefits of new drug therapies for neonatal seizures." @default.
• W2142300947 created "2016-06-24" @default.
• W2142300947 creator A5003672781 @default.
• W2142300947 creator A5020638606 @default.
• W2142300947 date "2008-08-01" @default.
• W2142300947 modified "2023-10-16" @default.
• W2142300947 title "Off-Label Use of Antiepileptic Drugs for the Treatment of Neonatal Seizures" @default.
• W2142300947 cites W1967090018 @default.
• W2142300947 cites W1973528305 @default.
• W2142300947 cites W1986250576 @default.
• W2142300947 cites W1987825891 @default.
• W2142300947 cites W2002369917 @default.
• W2142300947 cites W2021188919 @default.
• W2142300947 cites W2074973858 @default.
• W2142300947 cites W2100001024 @default.
• W2142300947 cites W2162332184 @default.
• W2142300947 cites W2322833765 @default.
• W2142300947 cites W4205283840 @default.
• W2142300947 doi "https://doi.org/10.1016/j.pediatrneurol.2008.04.008" @default.
• W2142300947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18639748" @default.
• W2142300947 hasPublicationYear "2008" @default.
• W2142300947 type Work @default.
• W2142300947 sameAs 2142300947 @default.
• W2142300947 citedByCount "124" @default.
• W2142300947 countsByYear W21423009472012 @default.
• W2142300947 countsByYear W21423009472013 @default.
• W2142300947 countsByYear W21423009472014 @default.
• W2142300947 countsByYear W21423009472015 @default.
• W2142300947 countsByYear W21423009472016 @default.
• W2142300947 countsByYear W21423009472017 @default.
• W2142300947 countsByYear W21423009472018 @default.
• W2142300947 countsByYear W21423009472019 @default.
• W2142300947 countsByYear W21423009472020 @default.
• W2142300947 countsByYear W21423009472021 @default.
• W2142300947 countsByYear W21423009472022 @default.
• W2142300947 countsByYear W21423009472023 @default.
• W2142300947 crossrefType "journal-article" @default.
• W2142300947 hasAuthorship W2142300947A5003672781 @default.
• W2142300947 hasAuthorship W2142300947A5020638606 @default.
• W2142300947 hasConcept C118552586 @default.
• W2142300947 hasConcept C126322002 @default.
• W2142300947 hasConcept C16568411 @default.
• W2142300947 hasConcept C177713679 @default.
• W2142300947 hasConcept C187212893 @default.
• W2142300947 hasConcept C197934379 @default.
• W2142300947 hasConcept C2777288759 @default.
• W2142300947 hasConcept C2777332695 @default.
• W2142300947 hasConcept C2777683783 @default.
• W2142300947 hasConcept C2778186239 @default.
• W2142300947 hasConcept C2908647359 @default.
• W2142300947 hasConcept C535046627 @default.
• W2142300947 hasConcept C71924100 @default.
• W2142300947 hasConcept C98274493 @default.
• W2142300947 hasConcept C99454951 @default.
• W2142300947 hasConceptScore W2142300947C118552586 @default.
• W2142300947 hasConceptScore W2142300947C126322002 @default.
• W2142300947 hasConceptScore W2142300947C16568411 @default.
• W2142300947 hasConceptScore W2142300947C177713679 @default.
• W2142300947 hasConceptScore W2142300947C187212893 @default.
• W2142300947 hasConceptScore W2142300947C197934379 @default.
• W2142300947 hasConceptScore W2142300947C2777288759 @default.
• W2142300947 hasConceptScore W2142300947C2777332695 @default.
• W2142300947 hasConceptScore W2142300947C2777683783 @default.
• W2142300947 hasConceptScore W2142300947C2778186239 @default.
• W2142300947 hasConceptScore W2142300947C2908647359 @default.
• W2142300947 hasConceptScore W2142300947C535046627 @default.
• W2142300947 hasConceptScore W2142300947C71924100 @default.
• W2142300947 hasConceptScore W2142300947C98274493 @default.
• W2142300947 hasConceptScore W2142300947C99454951 @default.
• W2142300947 hasIssue "2" @default.
• W2142300947 hasLocation W21423009471 @default.
• W2142300947 hasLocation W21423009472 @default.
• W2142300947 hasOpenAccess W2142300947 @default.
• W2142300947 hasPrimaryLocation W21423009471 @default.
• W2142300947 hasRelatedWork W1411351401 @default.
• W2142300947 hasRelatedWork W1970983388 @default.
• W2142300947 hasRelatedWork W1974806456 @default.
• W2142300947 hasRelatedWork W2047168413 @default.
• W2142300947 hasRelatedWork W2085804347 @default.
• W2142300947 hasRelatedWork W2373904487 @default.
• W2142300947 hasRelatedWork W2596995884 @default.
• W2142300947 hasRelatedWork W2738296467 @default.
• W2142300947 hasRelatedWork W3031461981 @default.
• W2142300947 hasRelatedWork W3184445563 @default.
• W2142300947 hasVolume "39" @default.
• W2142300947 isParatext "false" @default.
• W2142300947 isRetracted "false" @default.
• W2142300947 magId "2142300947" @default.
• W2142300947 workType "article" @default.